Middle East & Africa Pulmonary Arterial Hypertension Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Drugs, Type, Route of Administration, and Distribution Channel

Description

List of Tables

The Middle East & Africa pulmonary arterial hypertension market is expected to grow from US$ 410.88 million in 2022 to US$ 535.74 Million by 2028; it is estimated to grow at a CAGR of 4.5% from 2022 to 2028.

Growing Patent Expiration to Offer Lucrative Opportunities for Middle East & Africa Pulmonary Arterial Hypertension Market Growth During Forecast Period

Patent expiry permits generic drugs to enter the market and diversify product offerings. A few patented products are expected to become off-patent in the coming years, which is likely to provide an enormous opportunity for generic formulation companies. Many pharma companies such as finds Care Ratings are already working to develop the generic version of patented products. After patent expiration, generic versions of drugs can become available. While consumers benefit from low prices, losing patent protection can expose pharmaceutical companies to growing competition. Thus, patent expiration is expected to offer an opportunity for generic drug manufacturers to enter a new market. Hence, the growing patent expiration is expected to offer lucrative opportunities for the Middle East & Africa pulmonary arterial hypertension market growth in the coming years.

Middle East & Africa Pulmonary Arterial Hypertension Market Overview

The Middle East & Africa pulmonary arterial hypertension market is segmented into the UAE, Saudi Arabia, South Africa, and the Rest of the Middle East & Africa. Saudi Arabia is expected to account for the largest market share during the forecasted period i.e., from 2022 to 2028. Saudi Arabia is estimated to register considerable pulmonary arterial hypertension market growth. Saudi Arabia is the largest economy in the Middle East, excelling in the growth of various research and development programs across the nation. The country is becoming well-known in the field of pharmaceutical manufacturing. Furthermore, Saudi Arabia is expected to positively impact the Middle East & Africa pulmonary arterial hypertension market due to various regulations and the high demand for PAH drugs in the country. Additionally, several organizations are increasing awareness and knowledge about PAH among the population of Saudi Arabia. For instance, Saudi Association for Pulmonary Hypertension (SAPH) is working to increase awareness among people and knowledge of pulmonary vascular diseases among medical professionals in Saudi Arabia. Further, the government of Saudi Arabia launched the Saudi Vision 2030 program to reduce oil dependence and diversify other sectors, including healthcare, which is leading to significant development in healthcare services and a high adoption rate of advanced medical technologies. Under Vision 2030, the Saudi Arabian Government plans to invest over US$ 65 billion to develop the healthcare infrastructure in the country by prioritizing local production of pharmaceuticals and medical devices. Thus, the increasing awareness about PAH and the launch of Saudi Vision 2030 is expected to fuel the growth of the Middle East & Africa pulmonary arterial hypertension market in Saudi Arabia in the coming years.

Middle East & Africa Pulmonary Arterial Hypertension Market Revenue and Forecast to 2028 (US$ Billion)

Middle East & Africa Pulmonary Arterial Hypertension Market Segmentation

The Middle East & Africa pulmonary arterial hypertension market is segmented on the basis of drugs, type, route of administration, distribution channel, and country.

Based on drugs, the Middle East & Africa pulmonary arterial hypertension market is segmented into endothelin receptor antagonists (ERAs), prostacyclin and prostacyclin analogs, sGC stimulators, and pde-5 dipsticks. In 2022, the prostacyclin and prostacyclin analogs segment registered the largest share in the Middle East & Africa pulmonary arterial hypertension market.

Based on type, the Middle East & Africa pulmonary arterial hypertension market is bifurcated into branded and generics. In 2022, the branded segment registered a larger share in the Middle East & Africa pulmonary arterial hypertension market.

Based on route of administration, the Middle East & Africa pulmonary arterial hypertension market is segmented into oral, intravenous/subcutaneous, and inhalational. In 2022, the oral segment registered the largest share in the Middle East & Africa pulmonary arterial hypertension market.

Based on distribution channel, the Middle East & Africa pulmonary arterial hypertension market is segmented into hospital pharmacies and clinics, online pharmacies, and retail pharmacies. In 2022, the hospital pharmacies and clinics segment registered the largest share in the Middle East & Africa pulmonary arterial hypertension market.

Based on country, the Middle East & Africa pulmonary arterial hypertension market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. In 2022, Saudi Arabia registered the largest share in the Middle East & Africa pulmonary arterial hypertension market.

Bayer AG, Gilead Sciences Inc, GSK Plc, Johnson & Johnson, Lupin Ltd, Novartis AG, Pfizer Inc, and Teva Pharmaceutical Industries Ltd are the leading companies operating in the Middle East & Africa pulmonary arterial hypertension market.

Reasons to Buy:

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Middle East & Africa pulmonary arterial hypertension market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the Middle East & Africa pulmonary arterial hypertension market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth Middle East & Africa market trends and outlook coupled with the factors driving the pulmonary arterial hypertension market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution

Product Code: BMIRE00028069

1. Introduction

1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
- 1.3.1 MEA Pulmonary Arterial Hypertension Market - By Drugs
- 1.3.2 MEA Pulmonary Arterial Hypertension Market - By Type
- 1.3.3 MEA Pulmonary Arterial Hypertension Market - By Route of Administration
- 1.3.4 MEA Pulmonary Arterial Hypertension Market - By Distribution Channel
- 1.3.5 MEA Pulmonary Arterial Hypertension Market - By Country

2. MEA Pulmonary Arterial Hypertension Market - Key Takeaways

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. MEA Pulmonary Arterial Hypertension Market - Market Landscape

4.1 Overview
4.2 MEA PEST Analysis
4.3 Experts Opinion

5. MEA Pulmonary Arterial Hypertension Market - Key Market Dynamics

5.1 Market Drivers
- 5.1.1 Growing Incidence of Pulmonary Arterial Hypertension
5.2 Market Restraints
- 5.2.1 Side Effects of Drugs Used for Treatment of Pulmonary Arterial Hypertension
5.3 Market Opportunities
- 5.3.1 Availability of Generics at Affordable Costs Due to Growing Patent Expiration
5.4 Future Trend
- 5.4.1 Rising Clinical Trials for Drugs Development to Treat Pulmonary Arterial Hypertension
5.5 Impact analysis

6. Pulmonary Arterial Hypertension Market - MEA Analysis

6.1 MEA Pulmonary Arterial Hypertension Market Revenue Forecast and Analysis

7. MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 - by Drugs

7.1 Overview
7.2 MEA Pulmonary Arterial Hypertension Market Revenue Share, by Drugs 2021 & 2028 (%)
7.3 Endothelin Receptor Antagonists (ERAs)
- 7.3.1 Overview
- 7.3.2 Endothelin Receptor Antagonists (ERAs): MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
7.4 Prostacyclin and Prostacyclin Analogs
- 7.4.1 Overview
- 7.4.2 Prostacyclin and Prostacyclin Analogs: MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
7.5 SGC Stimulators
- 7.5.1 Overview
- 7.5.2 sGC Stimulators: MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
7.6 Pde-5 Dipsticks
- 7.6.1 Overview
- 7.6.2 Pde-5 Dipsticks: MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)

8. MEA Pulmonary Arterial Hypertension Market Analysis and Forecasts to 2028 - by Type

8.1 Overview
8.2 MEA Pulmonary Arterial Hypertension Market, by Type 2021 & 2028 (%)
8.3 Branded
- 8.3.1 Overview
- 8.3.2 Branded: MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
8.4 Generics
- 8.4.1 Overview
- 8.4.2 Generics: MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)

9. MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 - by Route of Administration

9.1 Overview
9.2 MEA Pulmonary Arterial Hypertension Market Revenue Share, by Route of Administration 2021 & 2028 (%)
9.3 Oral
- 9.3.1 Overview
- 9.3.2 Oral: MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
9.4 Intravenous/ Subcutaneous
- 9.4.1 Overview
- 9.4.2 Intravenous/ Subcutaneous: MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
9.5 Inhalational
- 9.5.1 Overview
- 9.5.2 Inhalational: MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)

10. MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 - by Distribution Channel

10.1 Overview
10.2 MEA Pulmonary Arterial Hypertension Market Revenue Share, by Distribution Channel 2021 & 2028 (%)
10.3 Hospital Pharmacies and Clinics
- 10.3.1 Overview
- 10.3.2 Hospital Pharmacies and Clinics: MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
10.4 Online Pharmacies
- 10.4.1 Overview
- 10.4.2 Online Pharmacies: MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
10.5 Retail Pharmacies
- 10.5.1 Overview
- 10.5.2 Retail Pharmacies: MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)

11. MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 - Country Analysis

11.1 Overview
- 11.1.1 Middle East & Africa: Pulmonary Arterial Hypertension Market, by Country, 2021 & 2028 (%)
  - 11.1.1.1 UAE: Pulmonary Arterial Hypertension Market Revenue and Forecasts to 2028 (US$ Million)
    - 11.1.1.1.1 Overview
    - 11.1.1.1.2 UAE: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
    - 11.1.1.1.3 UAE: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
    - 11.1.1.1.4 UAE: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
    - 11.1.1.1.5 UAE: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
    - 11.1.1.1.6 UAE: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
  - 11.1.1.2 Saudi Arabia: Pulmonary Arterial Hypertension Market Revenue and Forecasts to 2028 (US$ Million)
    - 11.1.1.2.1 Overview
    - 11.1.1.2.2 Saudi Arabia: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
    - 11.1.1.2.3 Saudi Arabia: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
    - 11.1.1.2.4 Saudi Arabia: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
    - 11.1.1.2.5 Saudi Arabia: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
    - 11.1.1.2.6 Saudi Arabia: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
  - 11.1.1.3 South Africa: Pulmonary Arterial Hypertension Market Revenue and Forecasts to 2028 (US$ Million)
    - 11.1.1.3.1 Overview
    - 11.1.1.3.2 South Africa: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
    - 11.1.1.3.3 South Africa: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
    - 11.1.1.3.4 South Africa: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
    - 11.1.1.3.5 South Africa: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
    - 11.1.1.3.6 South Africa: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
  - 11.1.1.4 Rest of the MEA: Pulmonary Arterial Hypertension Market Revenue and Forecasts to 2028 (US$ Million)
    - 11.1.1.4.1 Overview
    - 11.1.1.4.2 Rest of the MEA: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
    - 11.1.1.4.3 Rest of the MEA: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
    - 11.1.1.4.4 Rest of the MEA: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
    - 11.1.1.4.5 Rest of the MEA: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
    - 11.1.1.4.6 Rest of the MEA: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)

12. MEA Pulmonary Arterial Hypertension Market - Industry Landscape

12.1 Overview
12.2 Organic Developments
- 12.2.1 Overview
12.3 Inorganic Developments
- 12.3.1 Overview

13. Company Profiles

13.1 Johnson & Johnson
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Gilead Sciences Inc
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Bayer AG
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Novartis AG
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 GSK Plc
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 Teva Pharmaceutical Industries Ltd
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 Lupin Ltd
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Pfizer Inc
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments

14. Appendix

14.1 About The Insight Partners
14.2 Glossary of Terms